Literature DB >> 18956219

Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome.

K G Lagos1, T D Filippatos, V Tsimihodimos, I F Gazi, C Rizos, A D Tselepis, D P Mikhailidis, Moses S Elisaf.   

Abstract

Patients with metabolic syndrome (MetS) usually have low high density lipoprotein cholesterol (HDL-C) levels. We determined the HDL distribution profile as well as the HDL-related lipoprotein associated phospholipase A(2) (HDL-LpPLA(2)) and paraoxonase-1 (PON1) activities in subjects with MetS (n = 189) but otherwise healthy. Age and sex-matched individuals (n = 166) without MetS served as controls. The lower HDL-C concentration in MetS patients was due to a reduction in both large and small HDL subclasses (P < 0.001 and P < 0.05, respectively). As the number of MetS components increased, the HDL phenotype comprised of a greater percentage of small HDL-3 and less large HDL-2 subclasses, resulting in a decreased HDL-2/HDL-3 ratio (P < 0.001 for all trends). Multivariate analysis revealed that HDL-2 levels and the HDL-2/HDL-3 ratio significantly and independently correlated with HDL-C (positively) and TG (negatively) levels. HDL-3 concentration significantly and independently positively correlated with HDL-C and TG levels. HDL-LpPLA(2) activity was decreased in MetS patients (P < 0.01), a phenomenon that may contribute to the defective antiatherogenic activity of HDL in MetS. PON1 activity did not differ between groups. We conclude that MetS, in addition to the decrease in HDL-C concentration, is associated with alterations in the HDL phenotype, which is comprised of a greater percentage of small HDL subclasses. Furthermore, HDL-LpPLA(2) activity is decreased in MetS patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18956219     DOI: 10.1007/s11745-008-3251-9

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  50 in total

Review 1.  Multiple actions of high-density lipoprotein.

Authors:  Matilda Florentin; Evangelos N Liberopoulos; Anthony S Wierzbicki; Dimitri P Mikhailidis
Journal:  Curr Opin Cardiol       Date:  2008-07       Impact factor: 2.161

Review 2.  The metabolic syndrome.

Authors:  Robert H Eckel; Scott M Grundy; Paul Z Zimmet
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

3.  PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme.

Authors:  A D Tselepis; C Dentan; S A Karabina; M J Chapman; E Ninio
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-10       Impact factor: 8.311

4.  Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria.

Authors:  Irene Gazi; Vasilis Tsimihodimos; Theodosios Filippatos; Eleni Bairaktari; Alexandros D Tselepis; Moses Elisaf
Journal:  Metabolism       Date:  2006-07       Impact factor: 8.694

5.  Small, dense lipoprotein particles and reduced paraoxonase-1 in patients with the metabolic syndrome.

Authors:  Marie-Claude Blatter Garin; Barbara Kalix; Alfredo Morabia; Richard W James
Journal:  J Clin Endocrinol Metab       Date:  2005-02-01       Impact factor: 5.958

6.  Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma.

Authors:  Irene Gazi; Evangelia S Lourida; Theodosios Filippatos; Vasilis Tsimihodimos; Moses Elisaf; Alexandros D Tselepis
Journal:  Clin Chem       Date:  2005-10-13       Impact factor: 8.327

7.  Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB.

Authors:  Vasilis Tsimihodimos; Sonia-Athena P Karabina; Afroditi P Tambaki; Eleni Bairaktari; John A Goudevenos; M John Chapman; Moses Elisaf; Alexandros D Tselepis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-02-01       Impact factor: 8.311

8.  Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase.

Authors:  M I Mackness; S Arrol; C Abbott; P N Durrington
Journal:  Atherosclerosis       Date:  1993-12       Impact factor: 5.162

Review 9.  Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet.

Authors:  Samir S Deeb; Alberto Zambon; Molly C Carr; Amir F Ayyobi; John D Brunzell
Journal:  J Lipid Res       Date:  2003-03-16       Impact factor: 5.922

Review 10.  Prevention and treatment of the metabolic syndrome.

Authors:  S S Daskalopoulou; D P Mikhailidis; M Elisaf
Journal:  Angiology       Date:  2004 Nov-Dec       Impact factor: 3.619

View more
  24 in total

1.  Modulation of macrophage fatty acid content and composition by exposure to dyslipidemic serum in vitro.

Authors:  Bruce X W Wong; Reece A Kyle; Kevin D Croft; Carmel M Quinn; Wendy Jessup; Bu B Yeap
Journal:  Lipids       Date:  2011-02-01       Impact factor: 1.880

2.  Lipoprint adequately estimates LDL size distribution, but not absolute size, versus polyacrylamide gradient gel electrophoresis.

Authors:  Krista A Varady; Benoît Lamarche
Journal:  Lipids       Date:  2011-09-21       Impact factor: 1.880

3.  Effect of soy on metabolic syndrome and cardiovascular risk factors: a randomized controlled trial.

Authors:  Massimiliano Ruscica; Chiara Pavanello; Sara Gandini; Monica Gomaraschi; Cecilia Vitali; Chiara Macchi; Beatrice Morlotti; Gilda Aiello; Raffaella Bosisio; Laura Calabresi; Anna Arnoldi; Cesare R Sirtori; Paolo Magni
Journal:  Eur J Nutr       Date:  2016-10-18       Impact factor: 5.614

4.  Small high-density lipoprotein (HDL) subclasses are increased with decreased activity of HDL-associated phospholipase A₂ in subjects with prediabetes.

Authors:  Theodosios D Filippatos; Evangelos C Rizos; Vasilios Tsimihodimos; Irene F Gazi; Alexandros D Tselepis; Moses S Elisaf
Journal:  Lipids       Date:  2013-04-02       Impact factor: 1.880

5.  Dyslipidemic diabetic serum increases lipid accumulation and expression of stearoyl-CoA desaturase in human macrophages.

Authors:  Bruce X W Wong; Reece A Kyle; Paul C Myhill; Kevin D Croft; Carmel M Quinn; Wendy Jessup; Bu B Yeap
Journal:  Lipids       Date:  2011-06-15       Impact factor: 1.880

6.  Lipoprotein subfraction profile and HDL-associated enzymes in sickle cell disease patients.

Authors:  Oktay H Ozturk; Yesim Can; Zafer Yonden; Sedat Motor; Gonul Oktay; Hasan Kaya; Mutay Aslan
Journal:  Lipids       Date:  2013-10-11       Impact factor: 1.880

Review 7.  The human paraoxonase gene cluster as a target in the treatment of atherosclerosis.

Authors:  Zhi-Gang She; Hou-Zao Chen; Yunfei Yan; Hongliang Li; De-Pei Liu
Journal:  Antioxid Redox Signal       Date:  2011-10-18       Impact factor: 8.401

Review 8.  Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?

Authors:  Aris P Agouridis; Christos V Rizos; Moses S Elisaf; Theodosios D Filippatos
Journal:  Rev Diabet Stud       Date:  2013-08-10

9.  Correlation between high density lipoprotein and monocyte subpopulations among stable coronary atherosclerotic heart disease patients.

Authors:  Rong-Hai Yang; Ying-Feng Liu; Xue-Jun Wang; Jian-Guang Liang; Jia-Chao Liu
Journal:  Int J Clin Exp Med       Date:  2015-09-15

10.  High density lipoprotein and cardiovascular diseases.

Authors:  Theodosios D Filippatos; Moses S Elisaf
Journal:  World J Cardiol       Date:  2013-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.